Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

979
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
979
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

1.2K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.2K
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

1.1K
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
1.1K
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

950
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
950
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

861
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
861
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.4K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders.

JAMA network open·2026
Same author

Impaired Hippocampal Circuitry and Memory Dysfunction in Schizophrenia.

Nature. Mental health·2026
Same author

High prevalence of CNS-directed autoantibodies in patients with schizophrenia.

bioRxiv : the preprint server for biology·2026
Same author

With No Surprises From the EMERGENT-4 Trial, Where Do We Go From Here?

The American journal of psychiatry·2026
Same author

Reply to "Xanomeline/Trospium Combination: Not Non-dopaminergic but a Novel Antidopaminergic Treatment for Schizophrenia".

Journal of clinical psychopharmacology·2025
Same author

Hippocampal perfusion abnormalities and treatment effects in acute phase of first-episode schizophrenia.

Schizophrenia research·2025

Related Experiment Video

Updated: Apr 5, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.1K

Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Marc W Manseau1, Donald C Goff2

  • 1Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|August 28, 2015
PubMed
Summary
This summary is machine-generated.

Cannabis use, especially during adolescence, elevates the risk of psychosis and schizophrenia, particularly in vulnerable individuals. Cannabidiol (CBD) shows promise for treating psychosis with potential anti-inflammatory and neuroprotective benefits.

Keywords:
Cannabinoidscannabidiolcannabisendocannabinoidpsychosisschizophrenia

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.3K
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

709

Related Experiment Videos

Last Updated: Apr 5, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.1K
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.3K
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

709

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Cannabis sativa use is linked to an increased risk of psychotic disorders, including schizophrenia, and earlier onset of symptoms.
  • Adolescent cannabis exposure poses the highest risk for psychosis in vulnerable individuals, such as those with a history of child abuse or family schizophrenia.
  • The endocannabinoid system plays a role in psychosis, with anandamide signaling being particularly important in the central nervous system.

Purpose of the Study:

  • To explore the relationship between cannabis use and psychosis, including schizophrenia.
  • To investigate the potential therapeutic role of cannabidiol (CBD) in managing cannabis-induced psychosis and schizophrenia.
  • To understand the neurobiological mechanisms underlying cannabis and psychosis.

Main Methods:

  • Review of existing evidence linking cannabis use to psychosis.
  • Examination of the effects of Δ(9)-Tetrahydrocannabinol (THC) and cannabidiol (CBD) on psychotic symptoms.
  • Analysis of the endocannabinoid system's role in schizophrenia pathophysiology.

Main Results:

  • Cannabis use, particularly during adolescence, is associated with an increased risk and earlier onset of psychosis, especially in genetically predisposed or abused individuals.
  • Δ(9)-Tetrahydrocannabinol (THC) can induce schizophrenia-like symptoms, while cannabidiol (CBD) may counteract these effects.
  • CBD demonstrates potential therapeutic benefits for psychosis and schizophrenia, possibly offering better tolerability and possessing anti-inflammatory and neuroprotective properties.

Conclusions:

  • Cannabis use is a significant risk factor for psychosis and schizophrenia.
  • Cannabidiol (CBD) presents a promising therapeutic avenue for psychotic disorders, warranting further clinical investigation.
  • Further human research is essential to establish the role of CBD and related compounds in treating psychosis.